The FDA Grants Approval to JELMYTO For Upper Tract Urothelial Cancer
source: pixabay.com

The FDA Grants Approval to JELMYTO For Upper Tract Urothelial Cancer

  According to a recent FDA press release, the agency has given its first approval for a drug developed specifically for adult patients diagnosed with upper tract, low-grade, urothelial cancer.…

Continue Reading The FDA Grants Approval to JELMYTO For Upper Tract Urothelial Cancer
A UNC Grad with Chiari Malformation Creates Product to Protect Against Epileptic Injury
source: pixabay.com

A UNC Grad with Chiari Malformation Creates Product to Protect Against Epileptic Injury

  Ashlyn Sanders was a graduate student at Duke University when she experienced her first seizure. The UNC alumna was shocked. She pursued an MRI, which ended up discovering a…

Continue Reading A UNC Grad with Chiari Malformation Creates Product to Protect Against Epileptic Injury
The First Ever “World Chagas Disease Day” Just Happened on April 14
Photo Credit:Content Providers(s): CDC/World Health Organization / Public domain

The First Ever “World Chagas Disease Day” Just Happened on April 14

  According to the UN News, the first ever World Chagas Disease Day was celebrated on April 14, 2020 to raise awareness for Chagas Disease, a rare disease spread by…

Continue Reading The First Ever “World Chagas Disease Day” Just Happened on April 14
TNFi Treatment Ineffective for Some Patients with Ankylosing Spondylitis
jarmoluk / Pixabay

TNFi Treatment Ineffective for Some Patients with Ankylosing Spondylitis

  According to Ankylosing Spondylitis News, a recent study has found that TNF inhibitors are often not effective treatments for patients with ankylosing spondylitis. Read the full study in BMC Rheumatology.…

Continue Reading TNFi Treatment Ineffective for Some Patients with Ankylosing Spondylitis
Luspatercept Demonstrates Further Benefits in Transfusion-Dependent Beta Thalassemia
source: pixabay.com

Luspatercept Demonstrates Further Benefits in Transfusion-Dependent Beta Thalassemia

According to a story from Hematology Advisor, the drug luspatercept (marketed as Reblozyl) recently demonstrated its ability to reduce transfusion burden in patients with beta thalassemia that depend on regular…

Continue Reading Luspatercept Demonstrates Further Benefits in Transfusion-Dependent Beta Thalassemia
Close Menu